D-0443-2024 Class III Terminated
FDA drug recall D-0443-2024 was initiated by Novitium Pharma LLC on Mar 25, 2024 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Jul 16, 2024). Affected quantity: 1,003 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 24, 2024
- Initiation Date
- Mar 25, 2024
- Termination Date
- Jul 16, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,003 bottles
Product description
Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-200-10
Reason for recall
Failed Impurities/Degradation Specifications
Distribution pattern
U.S. Nationwide
Code information
Lot M23011A; Exp. 12/2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0443-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026